Применение ботулинического токсина типа А у больных с идиопатической детрузорной гиперактивностью
Применение ботулинического токсина типа А у больных с идиопатической детрузорной гиперактивностью
Мазо Е.Б., Кривобородов Г.Г., Васильев А.В. Применение ботулинического токсина типа А у больных с идиопатической детрузорной гиперактивностью. Consilium Medicum. 2008; 10 (2): 11–13.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760–6.
2. Schurch B, Stohrer M, Kramer G et al. Botulinum toxin-A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholenergic drugs. J Urol 2000; 164: 692–7.
3. Abrams P, Cardozo L, Fall M et al. The Standardisation of Terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodynam 2002; 21: 167–78.
4. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50 (suppl. 6A): 55.
5. Boone TB, Payne CK, Gormlrey. Diagnosis and treatment of urge incontinence. AUA News 2000; 5 (6): 9–10.
6. Appell RA, Diokho A, Antoci J et al. One-year, prospective, open-label trial of controlled-release oxybutinin for overactive bladder in a community-based population [abstract]. Neurourol Urodyn 2000; 19: 526.
7. Frenkl TL, Rackley RR. Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin N Am 2005; 32: 89–99.
8. Radziszewski P, Dobronski A, Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A – a pilot study [abstract]. Neurourol Urodyn 2001; 20: 410–12.
2. Schurch B, Stohrer M, Kramer G et al. Botulinum toxin-A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholenergic drugs. J Urol 2000; 164: 692–7.
3. Abrams P, Cardozo L, Fall M et al. The Standardisation of Terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodynam 2002; 21: 167–78.
4. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50 (suppl. 6A): 55.
5. Boone TB, Payne CK, Gormlrey. Diagnosis and treatment of urge incontinence. AUA News 2000; 5 (6): 9–10.
6. Appell RA, Diokho A, Antoci J et al. One-year, prospective, open-label trial of controlled-release oxybutinin for overactive bladder in a community-based population [abstract]. Neurourol Urodyn 2000; 19: 526.
7. Frenkl TL, Rackley RR. Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin N Am 2005; 32: 89–99.
8. Radziszewski P, Dobronski A, Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A – a pilot study [abstract]. Neurourol Urodyn 2001; 20: 410–12.
Авторы
Е.Б.Мазо, Г.Г.Кривобородов, А.В.Васильев
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.